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ABSTRACT 
 
 
 A preventive vaccine for HIV infection is urgently needed to curb the 
HIV/AIDS pandemic. To date only one human trial testing the combination of an 
ALVAC-HIV/gp120 protein strategy (Thai trail) has resulted in some protection 
from HIV infection. The correlate of protection elicited by this vaccine strategy 
was non-neutralizing antibodies to the gp120 protein. Nevertheless, the overall 
efficacy of the Thai trial was limited (31.2%); indicating that more work needs to 
be performed to ameliorate the Thai trial vaccine efficacy.  
 T Follicular Helper (TFH) cells are subset of CD4 T cells that localize 
within the follicular region of lymph nodes, are required for the formation and 
maintenance of the germinal center, and provide help to B cells. TFH may 
therefore be critical for the development of effective antibodies to HIV/SIV. Here, 
we characterize TFH in different lymphoid compartments of naïve and infected 
rhesus macaques, the preferred animal model to assess the efficacy of candidate 
vaccines for HIV. First, we looked at the frequency of TFH within the various 
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lymphoid compartments. TFH, characterized as PD-1++, ICOS++ and CCR7-, 
were higher within the spleen, the lamina propria of the rectal mucosa, and the 
tonsils than the lymph nodes. Interestingly, during chronic SIV infection, the 
frequency of TFH significantly increased in the lymph nodes while remaining 
fairly constant in the spleen. We then functionally characterized TFH in the lymph 
nodes of infected and non-infected macaques by performing an intracellular 
cytokine staining to measure the production of IFN-γ, TNF-α, IL-17, and IL-21 
after in vitro stimulation with PMA-ionomycin and SIV-env and SIV-gag 
overlapping peptides. Interestingly, while TFH (CCR7-/PD-1++) and non-TFH 
were capable of producing IFN-γ, TNF-α and IL-21 after stimulation with PMA-
ionomycin, in chronically infected animals, we observed an impaired production 
of IL-21.  
 As localization in the germinal center is believed to be relevant for TFH 
functionality, we established a migrational assay as a way to better discriminate 
TFH from non-TFH in macaques. The aim was to mimic the in vivo migration of 
non-TFH to the T cell zone and of TFH to the B cell zone of the lymph nodes, 
induced by CCL19/CCL21, and CXCL13, respectively, using a two-step assay. 
We obtained an enrichment of phenotypic defined non-TFH (first migration: 
CCL19/CCL21) and TFH cells (second migration: CXCL13) from lymph nodes 
from both naïve and infected macaques. We show that CD4 T cells from naïve 
macaques that migrated to the CXCL13 had higher levels of Bcl-6 expression 
and were capable of producing higher levels of IL-21 and lower levels of IFN-γ 
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than cells that migrated to the CCL19 and CCL21-T zone chemokines.  
Additionally, in SIV infected macaques, CD4 T cells that migrated to CXCL13 
were impaired in the production of IL-21 following stimulation with PMA-
ionomycin. These results validate our two-step migration assay as an innovative 
way to study TFH in macaques. 
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INTRODUCTION 
 
 Human Immunodeficiency Virus (HIV) is a global pandemic. HIV infects 
thirty-four million individuals with more than 2 million new infections per year 
(UNAIDS, 2012). If left untreated, HIV infection results in most cases in Acquired 
Immunodeficiency Syndrome (AIDS) and death. In total, there were 
approximately 1.8 million AIDS-related deaths in 2011. Although HIV is spread 
globally, the regions most affected are Sub-Saharan Africa and South East Asia 
containing 1.2 million and 250,000 adult and child AIDS-related deaths in 2011, 
respectively (Organization, 2011). The human and economical consequences of 
the HIV pandemic catalyzed the rapid discovery of antiretroviral therapy (ART), 
which has effectively curbed the total number of AIDS-related deaths within the 
past decade (UNAIDS, 2012). However, there are a number of inherent problems 
that lie within ART, such as the failure to eradicate the viral reservoir, the limited 
success at preventing viral replication at mucosal sites, and the unfavorable side 
effects associated with treatment (Barton, Burch, Soriano-Sarabia, & Margolis, 
2013; Pinzone, Di Rosa, Cacopardo, & Nunnari, 2012; Wasti et al., 2012). 
Moreover, the high cost burden associated with ART hinders its widespread 
global use, particularly in resource-limited regions where HIV/AIDS is most 
prevalent and the drugs are most needed (Riyarto et al., 2010). These downsides 
have highlighted the importance of a preventative vaccine capable of being 
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implemented on a global scale as well as a cure aimed at the complete 
eradication of the virus from chronically infected individuals.  
 Historically, the search for an HIV vaccine has been challenging due to the 
intrinsic characteristics of the glycoprotein (gp) 120 envelope protein. While an 
effective vaccine for HIV should likely induce neutralizing antibodies (nAbs) to 
gp120 in order to block the interaction between the virus and target cells, the 
generation of these antibodies to HIV has proven difficult (McMichael, Borrow, 
Tomaras, Goonetilleke, & Haynes, 2010). Besides the virus itself, no other 
immunogen that can elicit protective nAbs to primary HIV isolates has been 
generated.  
  Finally, however, the results of the RV144 vaccine trial from Thailand in 
2009 in showed limited but significant protection (31.2%) against HIV acquisition 
(Rerks-Ngarm et al., 2009). Despite this finding, protection appears to decrease 
with time and this vaccine strategy failed to protect against high viral replication 
and CD4 T-cell loss among vaccinated individuals that became infected. 
Subsequent data has identified gp120-specific non-neutralizing antibodies 
(NnAbs) to be correlated with protection (Haynes et al., 2012). Moreover, the 
importance of antibodies to gp120 in protection from HIV infection has been 
validated in several pre-clinical studies using various vaccine strategies (Bialuk et 
al., 2011; Pegu et al., 2013; Strbo et al., 2013; Vaccari, Halwani, et al., 2013).   
 Recently, a new CD4 T cell subset termed T Follicular Helper (TFH) cells 
has been discovered (Schaerli et al., 2000). TFH localize in the B cell zone of 
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lymphoid tissues where they support B cell maturation, affinity maturation, and 
class switch recombination (CSR) (Crotty, 2011). The importance of B cell 
responses in the RV144 vaccine strategy suggests that vaccine-induced CD4 T 
helper cells may play a role in the establishment and development of both 
plasma cells and productive antibodies. Thus, expanding our knowledge on the 
role of TFH in HIV pathogenesis and of vaccine-induced TFH in protection from 
HIV infection may be critical for improving the efficacy of current HIV vaccine 
strategies through the induction of protective antibodies that persist overtime. 
 
Human Immunodeficiency Virus 
 Structure and Genome 
 HIV is a lentivirus whose genome consists of two single-stranded RNA 
molecules, each containing structural (env, gag, pol) as well as regulatory and 
accessory (tat, rev, nef, vif, vpr, vpu) genes that encode for several peptides after 
post-transcriptional and post-translational processing (Figure 1). An outer lipid bi-
layer envelope acquired from the host cell membrane during budding is studded 
with several molecules of Env protein and host-derived surface molecules, 
characterizing the external features of HIV (Briggs & Krausslich, 2011). 
 The env gene encodes a protein, gp160, that is cleaved by a cellular 
enzyme to form the outer gp120 and transmembrane gp41 molecules. The  
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Figure 1. Genomic Organization of HIV-1. Depicted are the structural (env, gag, pol) and 
accessory (tat, rev, nef, vif, vpr, and vpu) genes alongside the function of encoded proteins. 
Adapted from Fauci A.S., 2012.  
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gp41 monomer is non-covalently linked to three gp120 molecules forming the 
Env peptide (Checkley, Luttge, & Freed, 2011). Much of the research to develop 
a vaccine to prevent HIV infection has focused on these envelope proteins. 
 The core of the virus that encases the single-stranded diploid RNA viral 
genome is composed of p17 and p24 proteins encoded by the gag gene. The 
gene pol encodes two enzymes: reverse transcriptase (RT), which transcribes 
viral RNA into double-stranded proviral DNA, and integrase, which integrates the 
provirus into the host's genome. Collectively, the proteins encoded by env, gag, 
and pol genes provide HIV with the components that allow the viral infection, 
replication, and expansion (Lu, Heng, & Summers, 2011).  
 Briefly, HIV has six regulatory genes (tat, rev, nef, vif, vpr, and vpu) that 
contain information needed to produce proteins that control the ability of HIV to 
infect cells, produce new viral copies, and cause disease. Proteins encoded by 
the genes nef, vif, vpr, and vpu have been collectively found to be associated 
with the infectivity of HIV as well as overall disease progression (Kartikeyan S, 
2007). Recently, a role for Vpu and Nef proteins has emerged that includes the 
ability of these proteins to degrade intracellular restriction factors, such as 
APOBEC3G and Tetherin, which target HIV (Harris, Hultquist, & Evans, 2012).  
 Replication 
 Upon invasion of the mucosal barrier, HIV infects cells that express the 
CD4 membrane receptor, such as T cells, macrophages, and dendritic cells. HIV 
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infection is a multistep process initiated by the interaction of gp120/41 with 
Cluster of Differentiation (CD) 4 that exposes the region of the gp120 able to 
interact with the chemokine (C-C motif) receptor 5 (CCR5) or chemokine (C-X-C 
motif) receptor 4 (CXCR4). This dual receptor interaction leads to a 
conformational change within gp120 that facilitates the fusion of viral and host 
cell membranes with the subsequent release of viral capsid and genomic RNA 
into the CD4 bearing cells. Infected cells then disperse throughout the lymphoid 
tissues, particularly the gut, which contain a large number of target cells: 
activated CD4 T cells expressing CCR5 and CXCR4. In these regions, 
widespread dissemination occurs culminating in a productive HIV infection 
(Blumenthal, Durell, & Viard, 2012; Cicala, Arthos, & Fauci, 2011). 
 Within cells, the viral capsid releases its contents and RT is used to 
transcribe copies of viral DNA (Figure 2). The viral DNA and associated peptides 
form a pre-integration complex that migrates into the nucleus of the host cell. 
After translocation, viral DNA is integrated within the host DNA and viral mRNA 
transcripts are formed alongside host transcription. Cellular activation by HIV 
broadly increases host transcription facilitating rapid HIV transcription. Viral 
mRNA translation utilizes host ribosomes to produce precursor peptides that are 
then processed via HIV derived protease. Within the cytoplasm, viral RNA, 
essential proteins and viral capsid aggregate in a process driven by Gag protein 
to form viral progeny that subsequently exit the cell via budding (Campbell & 
Vogt, 1995; Meng & Lever, 2013).   
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Figure 2. HIV Replication Cycle. Adapted from Facui, A.S., 2012. 
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SIV and the macaque model of HIV infection 
 The recognition of an AIDS-like disease in macaques led to the isolation of 
Simian Immunodeficiency Virus (SIV) with the subsequent identification of 
several other SIV subtypes with variable degrees of pathogenicity from an 
assortment of nonhuman primate (NHP) species (Staprans & Feinberg, 2004).  
Collectively, the SIV variants contain striking structural and genomic homology to 
HIV. Virus strains from two of these primate species, SIVsmm in sooty 
mangabeys and SIVcpz in chimpanzees, are thought to have crossed the 
species barrier into humans, resulting in HIV-2 and HIV-1, respectively (Pepin, 
2011). In natural hosts, SIV infections are largely non-pathogenic. Extensive 
studies in sooty mangabeys have established that SIVsmm infection does not 
cause disease in these animals, despite high levels of viral replication. However, 
if the virus infects non-natural hosts, such as Asian or Indian Rhesus macaque, 
the animal will develop simian AIDS (SAIDS) (Kestler et al., 1990). To more 
accurately reflect the pathogenesis of HIV, molecularly enhanced SIV clones 
have been created with increased virulence.   
 The genetic and biological similarities between SIV and HIV provide a 
suitable model for HIV infection. SIV infected macaques and chimpanzees 
closely mirror HIV infection and the disease progression to AIDS. These animals 
have therefore been extensively studied in the context of HIV pathogenesis and 
candidate vaccines. Research in the last two decades has focused on the use of 
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SIV in macaques, which unlike chimpanzees are not endangered and can be 
easily bred in captivity. 
 Specifically, SIV infection in macaques is similar to HIV infection in 
humans in that: 
 SIV is a CCR5-tropic virus that replicates optimally in activated memory 
CD4 T cells, thus resulting in profound and selective depletion of CD4 T 
cells in the intestine within days of infection (Veazey et al., 1998); 
 Infection with SIV overtime results in decreased CD4 T cell levels in the 
blood (Okoye et al., 2007); 
 Kinetics of SIV infection is characterized by a peak of viral replication 
(Acute phase) followed by a set point and a chronic phase (Lackner & 
Veazey, 2007);  
 Several host genetic factors permit the control of SIV infection in 
macaques. Notably, Major Histocompatibility Complex (MHC) I alleles 
Mamu*01, Mamu*08, and Mamu*B17 are associated with better outcomes 
after infection by SIV (Staprans & Feinberg, 2004). In humans, Human 
Leukocyte Antigen (HLA) - B alleles have also been associated with 
protection against HIV/AIDS progression (Emu et al., 2008); 
 Some macaques do not progress to disease similar to recently described 
human elite controllers that are resistant to the development of AIDS 
(Zhang et al., 2002). Some macaques also rapidly progress to disease. 
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Contrary to HIV, SIV is more virulent than HIV-1 (Lackner & Veazey, 2007). The 
set point of viremia in SIV-infected macaques is 10- to 100-fold higher than in 
HIV-1 infection, and progression to AIDS occurs in 1–2 years (Picker, Hansen, & 
Lifson, 2012). 
 Furthermore, the paralleled immune system of humans and macaques 
provides the opportunity to gain a detailed understanding of HIV/AIDS 
pathogenesis and to test candidate vaccines for HIV in this model. More 
importantly, this model offers the unique ability to carefully sample different 
tissues in the attempt to determine possible correlates of protection from high 
viral replication and acquisition of infection. Notably, studies in macaques during 
acute infection have identified SIV-specific CD8+ and CD4+ T cells to be 
correlated with the reduction of peak viremia, the maintenance of SIV RNA levels 
in chronic infection, and delayed progression to disease (Freel, Saunders, & 
Tomaras, 2011; Hel et al., 2001). In fact, studies have shown that when CD8+ or 
CD4+ T cells are depleted in vivo from macaques, there is a loss of viral control 
leading to a substantial increase in viral loads (Jin et al., 1999; Schmitz et al., 
2005; Vaccari et al., 2008). 
 Studies involving the passive transfer of antibodies conducted in this 
animal model have shown the potential of nAbs to block infection (Mascola et al., 
2000). Also, in the context of SIV vaccines, vaccine-induced NnAbs that promote 
antibody-dependent cellular cytotoxicity (ADCC) have been correlated with 
protection from SIV infection. Moreover, these antibodies have also been 
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associated with reduced plasma viral loads and delayed disease progression, 
even when protection is not elicited (Gomez-Roman et al., 2005). 
 The role of the non-human primate model of HIV as a gate-keeper for 
candidate vaccines has been recently debated (Shedlock, Silvestri, & Weiner, 
2009). Strategies that appeared to protect macaques from SIV infection, such as 
the adenovirus-based vector Ad5, failed to protect humans vaccinated with 
similar modalities (Gray et al., 2011; Shiver et al., 2002). However, the SIV 
isolate used in these studies was not CCR5-tropic and was therefore not relevant 
to HIV infectivity of humans. Studies in macaques using SIVmac251 and a 
vaccine strategy similar to the RV144 vaccine have resulted in different degrees 
of protection depending upon the dose of the virus used. Thus, the focus has 
recently been turned to retool this model to be more predictive of results obtained 
in human trials, thanks to the partial success of the Thai trials. Two recent 
studies have recapitulated the Thai trial in macaques and shown that protection 
from HIV acquisition, similar to that of the human trial, can be obtained in 
macaques when challenged with a repeated low dose challenge of SIVmac251, 
rather than a single high dose. (Pegu et al., 2013; Vaccari, Keele, et al., 2013). 
Thus, future studies utilizing repeated low-dose challenges in macaques will 
likely be more predictive of vaccine efficacy in humans considering the 
appropriate SIV isolate is used.  
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HIV/SIV induced immunopathology 
 AIDS/SAIDS is a disease caused by HIV/SIV in which cellular immune 
functions are severely impaired. Both HIV and SIV immune abnormalities are 
seen early in infection and include immune hyperactivation and autoimmune 
phenomena suggestive of immune dysregulation and immune deficiency.  
 The earliest stages of HIV infection specifically target mucosal memory 
CD4 T cells, which then spread throughout various lymphoid compartments. In 
particular, the gut-associated lymphoid tissue (GALT) is preferentially targeted 
due to an enrichment of memory CD4 T cells expressing high levels of CCR5 
(Anton et al., 2000; Cicala et al., 2011). Widespread infection within the GALT 
leads to a 60-80% depletion of CD4 T cells that persists throughout infection 
(Brenchley et al., 2004; Mattapallil et al., 2005; Veazey et al., 1998). This 
destruction is also reflected in the peripheral blood memory CD4 T cell 
population that is followed by a CD4 T cell rebounding as the viral set point is 
reached (McMichael et al., 2010). The loss of T helper cells clearly affects the 
generation and maintenance of durable and long lasting memory response. 
Therefore, rather than being confined to only infected cells, the detriment of 
HIV/SIV infection is widespread and encompasses all arms of the immune 
system.  
 A well-known hallmark of HIV/SIV infection is a state of chronic immune 
activation that has been associated with: 
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• B and T cell apoptosis and an increased expression of pro-apoptotic 
molecules such as tumor necrosis factor (TNF), Fas Ligand (CD95L), and 
TNF-related apoptosis inducing ligand (Trail) (Gasper-Smith et al., 2008). 
• Increased markers of exhaustion such as Programmed death 1 (PD-1). 
The accumulation of exhausted virus-specific T cells has been correlated 
with the inability of the immune response to control viral replication during 
chronic HIV infection (Ha et al., 2008; Petrovas et al., 2007).  
• Skewing from Interleukin (IL)-2 towards Interferon gamma (IFN-γ) 
secretion by virus specific CD8 T cells has been observed and is 
associated with a loss of viral control as HIV/SIV progresses (Harari et al., 
2007; Trautmann et al., 2012). Also, the function of CD8 T cells is 
compromised resulting in cells with a reduced proliferative capacity and a 
polyfunctional shift from cells secreting multiple cytokines to those with 
limited cytokine production (Migueles et al., 2009). 
• Increased T regulatory cells (Treg) and markers for T cell suppression. As 
a possible attempt to decrease activation, Tregs accumulate in different 
tissues and decreases the overall ability of the immune system to 
response to the virus (M. F. Chevalier & Weiss, 2013). 
• Increased Lipopolysaccharide (LPS) levels in the plasma. Studies have 
proposed a microbial leakage from the gut of infected patients and 
monkeys, due to their compromised gastrointestinal mucosal surface 
(Brenchley et al., 2006; Jiang et al., 2009). 
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While immune activation is to some extent beneficial in partially restoring 
depleted memory CD4 T cells and potentiating HIV-specific immune responses, 
chronic immune activation has been associated with disease progression 
(Douek, Roederer, & Koup, 2009). As mentioned previously, SIV infection in 
natural hosts, African Green monkey (AGM) and Sooty Mangabey (SM), does 
not cause disease whereas infection in non-natural hosts, rhesus macaques 
(RM), leads to SAIDS (Liovat, Jacquelin, Ploquin, Barre-Sinoussi, & Muller-
Trutwin, 2009; Paiardini, Pandrea, Apetrei, & Silvestri, 2009). Two recent studies 
comparing the dynamics of acute SIV infection between, AGM, RM and SM 
reported a strong upregulation of type I IFN-stimulated genes (ISG) in both AGM 
and RM (Bosinger et al., 2009; Jacquelin et al., 2009). However, ISG expression 
returned to pre-infection levels within four weeks of infection in the AGM, but not 
the RM. The accompanying report demonstrated that non-pathogenic SIV 
infection induces a strong innate immune response, immune activation, and 
expression of ISG, followed by rapid resolution of the above activation markers. 
In contrast, the pathogenesis-susceptible RM maintained a chronic state of 
immune activation and ISG expression that correlated with T cell exhaustion 
marker, LAG3. LAG3 was not activated in the pathogenesis-resistant SM. These 
findings are consistent with the hypothesis that chronic innate immune activation 
contributes to the immunopathogenesis induced by HIV (Douek et al., 2009; 
McMichael et al., 2010). Briefly, Dendritic and Natural Killer cells are other types 
of cells that are indirectly and directly affected by HIV/SIV. 
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CD4 T cell subsets and HIV/SIV infection 
 There are several clearly defined subsets of CD4 T cells each with its own 
phenotype and function, none of which are protected from infection. HIV 
differentially affects each subset. The most abundant of these cells, T Helper 
(Th) 1 and Th2, each secrete a variety of cytokines that provide help to cellular 
and humoral immune responses, respectively. During acute infection, the Th1 
mediated response appears to dominate Th2 responses. Through the release of 
soluble cytokines, Th1 cells indirectly control viremia by aiding the cytotoxic CD8 
T cell response. Eventually, however, a T cell switch occurs and Th2 responses 
begin to dominate, driving the humoral responses (Klein et al., 1997). The Th1 
Th2 switch often corresponds with disease progression highlighting the 
importance of a functional Th1 response in mediating CD8 T cell cytotoxicity 
(Clerici & Shearer, 1993). Indeed, HIV elite controllers typically have well-
established Th1 and Th2 responses capable of maintaining both cellular and 
humoral immune responses simultaneously (Imami et al., 2002).  
 Th17 cells, defined by their ability to produce IL-17, are critical in 
maintaining the integrity of the GALT. In particular, they serve as a defense 
against intestinal bacteria (Dandekar, George, & Baumler, 2010). During HIV 
infection, these cells are preferentially infected and depleted without restoration, 
even upon ART initiation. 
 TFH cells, also susceptible to HIV/SIV infection, play a critical role in the 
formation of the germinal center (GC) and effective humoral immune responses. 
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Interestingly, TFH cells do not undergo the typical depletion observed in other 
CD4 T cell subsets and some have reported an expansion or accumulation of 
TFH cells during HIV/SIV infection (Lindqvist et al., 2012; Petrovas et al., 2012). 
Despite these apparently controversial data, there is an overall lack of functional 
information regarding TFH during HIV/SIV infection. Defining the function of 
these cells during infection is critical for identifying HIV/SIV specific TFH 
responses that may provide insight for the development of vaccine strategies that 
elicit protection from acquisition of HIV.  
 
Correlates of protection for HIV/SIV infection 
 Identifying correlates of protection from HIV/SIV infection and disease 
progression is important in identifying potential vaccine targets. The ideal source 
to define correlates of protection from AIDS is directly from infected patients 
capable of controlling the virus. However, these patients are exceedingly rare 
and a detailed examination of their immune system is not feasible. Macaques are 
an available resource that, as mentioned previously, is capable of controlling 
disease progression in some animals. Macaques can be genetically engineered 
to express SIV and SAIDS controlling genotypes and can be examined in more 
depth than humans. This allows for a detailed examination of immune responses 
that may contribute to protection from SAIDS.  
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• Cellular Immune Responses 
 Shortly after viral dissemination, as the viral load begins to rise in the 
plasma, a CD8 cytotoxic T cell response is mounted and directed toward 
conserved regions of Env and Nef proteins (McMichael et al., 2010). This early 
CD8 T cell response is capable of effectively controlling viral replication and 
reducing the viral load from its peak to the viral set point.  Once reached, the set 
point is maintained by later CD8 T cell responses specific to Gag p24 and Pol 
proteins. This same relationship between the CD8 T cell responses and viral load 
is observed in SIV infected macaques, as mentioned previously. Furthermore, a 
well-established HIV-specific CD8 T cell response has been observed in HIV elite 
controllers whereas rapid progressors tend to lack this response (Betts et al., 
2006).  CD8 T cells can be divided into central memory, effector memory and 
terminally differentiated effectors based on the expression of surface markers 
such as CD95 (Fas) apoptotic molecule and CD28 co-stimulatory molecule, and 
also based on their location. While central memory (CD28+/CD95+) T cells have 
been found to be correlated against protection with viral replication, terminally 
differentiated CD8 (CD28-/CD95+) T cells present at the mucosal sites have been 
associated with protection from SIV acquisition (Vaccari, Halwani, et al., 2013). 
 Despite being the target of HIV infection, an elegant study in mice has 
shown the importance of CD4 T helper cells to maintain long-term memory of 
CD8 T cells (Ramsburg, Publicover, Coppock, & Rose, 2007). The dual role of 
CD4 T cells has been assessed in preventive vaccination studies in macaques. 
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The frequency of specific CD4 T cells induced by vaccination was correlated with 
protection from SIV replication, and in vivo depletion of vaccine induced CD4 T 
cells before the challenge resulted in faster progression to disease (Pal et al., 
2002; Vaccari et al., 2008). Of note, the cellular specific responses induced by 
the strategy used in the Thai trial are mainly CD4 T cells. 
• Humoral Immune Responses 
 Almost all current available vaccines that protect from human pathogens 
appear to work through induction of antibodies in the serum or mucosa that block 
infection or interfere with microbial invasion. This suggests that antibody 
responses against HIV may be key in protection from viral acquisition and 
replication. Passive transfer of nAbs in nonhuman primate studies has 
successfully elicited protection from SIV acquisition, but thus far, induction of 
nAbs has not been possible with current vaccine strategies (Langedijk & 
Schuitemaker, 2012; Mascola et al., 2000). In natural HIV infection, nAbs are 
measurable after many weeks following infection, and are characterized by an 
overall narrow breadth. These early phase nAbs tend to lag behind viral escape 
mutants and are largely ineffective at controlling the virus, thus failing to 
contribute to the reduction of the peak viremia and/or to the maintenance of low 
viral replication (Alter & Moody, 2010). In a small minority of patients, broadly 
nAbs, antibodies capable of neutralizing many virus variants with a strong 
potency have been shown to arise years after infection. However, they are 
ineffective in delaying the progression to AIDS (Euler & Schuitemaker, 2012). 
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The earliest HIV-specific antibody responses found in the plasma of acute 
infected subjects are NnAbs. These antibodies are directed toward gp41 and 
gp120 and emerge approximately 2 weeks post-infection. Although capable of 
binding to envelope regions, these antibodies fail to induce antibody-dependent 
cell-mediated viral inhibition (ADCVI) (Tomaras & Haynes, 2009).  
 Despite the inability to produce vaccine-induced nAbs, NnAbs induced by 
vaccination in humans and macaques have recently emerged as a correlate of 
protection from HIV/SIV infection. (Florese et al., 2009; Haynes et al., 2012; Xiao 
et al., 2010). In these trials, vaccine-induced env-specific NnAbs mediating 
ADCC were correlated with protection from HIV/SIV infection. This suggests that 
the induction of NnAbs through vaccination may be important to the generation of 
an effective HIV vaccine.  
 
Lessons Learned from Human HIV Vaccine Trials 
 After the identification of HIV as the cause of AIDS in 1983, there was an 
expectation that a preventative HIV vaccine would soon follow. Thirty years of 
intense research efforts have provided crucial information on the virus and the 
disease, but an effective HIV vaccine has not yet been identified. To date, only 3 
vaccine strategies have advanced to phase III efficacy trials in humans: an 
Adenovirus based vector (Step trial/HVTN 502/Merck), inducing T-cell 
responses; a gp120 protein vaccine (AIDSVAX, VAXGENE) inducing antibodies 
to the HIV envelope; and a Canarypox-based vector (Thai Trial, RV144) plus 
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gp120 protein inducing low T-cell responses and antibodies (Flynn et al., 2005; 
Gray et al., 2011; Haynes et al., 2012). While the first 2 trials failed, showing that 
inducing either cell-mediated immunity or humoral immunity is inadequate for 
protection, the RV144 vaccine trial provided some level of protection from HIV 
acquisition. 
 The Thai trial is the largest vaccine efficacy trial ever conducted, enrolling 
16,000 Thai men and women at low risk for HIV infection. The immunization 
strategy used in this trial is a combination of two vaccines given in a prime-boost 
fashion: the ALVAC-HIV (virus recombinant Canarypox vCP1521) and AIDSVAX 
(glycoprotein gp120). The ALVAC-HIV expressed gag, protease, and envelope 
from HIV Clade B and a circulating form of clade A, A/E, most prevalent in 
Thailand. Two gp120 proteins from both clades were given simultaneously at the 
last two immunizations with the ALVAC-HIV vector. The vaccine strategy used 
consisted of four separate immunizations spanning over a six-month period. 
Subjects were immunized with ALVAC-HIV intramuscularly at weeks 0, 4, 12 and 
24, with AIDSVAX B/E with alum adjuvant being give in the contralateral muscle 
during the last two immunizations (Vaccari, Poonam, & Franchini, 2010).  
 In summary, the surprising results of the Thai trial proved for the first time 
that the development of a fully protective vaccine for HIV may be possible. The 
vaccine regimen provided a 31.2% efficacy against acquisition of HIV. 
Nevertheless, the vaccine failed to reduce viral replication post-infection as there 
was no significant difference between viral loads of HIV infected subjects 
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belonging to vaccinated and placebo groups (Rerks-Ngarm et al., 2009). 
Furthermore, the durability of the vaccine has been called into question as the 
protection appears to wane over time.   
 Although the trial was not powered to identify immune correlates of 
protection, analyses of sera have shed light on protective vaccine-induced 
immune responses. Contrary to what many believed is required for an effective 
HIV vaccine, the Thai trial vaccine did not induce specific CD8 T cells or nAbs, 
but rather induced env-specific CD4 T-cells and NnAbs that mediate ADCC 
(Haynes et al., 2012). The binding Immunoglobulun (Ig) G antibodies that were 
highly correlated with protection were directed to the V1V2 loop of gp120, which 
contains the binding site to the α4β7 integrin. Thus it may be possible to increase 
the efficacy of this vaccine by inducing higher titer or better “quality” of B cell 
responses. It is also possible that the generation of CD4 T cells that provide the 
right type of help to humoral responses may be important.  
 The results of the Thai trail have been recently recapitulated in an 
exploratory study in macaques. Although not powered to yield protection, 3 out of 
11 macaques (27.3%) immunized with an ALVAC-SIV/gp120 strategy were 
protected from SIV acquisition. Protected animals were found to produce 
antibodies of higher avidity directed toward gp120 compared to non-protected 
animals. This difference was lost when the V1V2 loop was removed from the 
gp120 used in the analysis. Additionally, similar to humans, macaques that 
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became infected were not protected from high viral replication or CD4 T-cell loss 
(Pegu et al., 2013).  
 
T Follicular Helper cells 
 The identification of CXCR5 expressing CD4 T cells in human tonsils in 
2000 provided early insight to a new CD4 T cell subset termed T Follicular Helper 
(TFH) cells. The expression of CXCR5, the receptor for the lymphoid follicle 
homing chemokine CXCL13, suggested infiltrative characteristics of these cells 
into the follicular regions of lymph nodes and a possible role in supporting the B 
cell maturation process. Indeed, these CXCR5+ CD4 T cells were found to aid in 
the humoral response and promoted IgG and IgA antibody responses when co-
cultured with B cells (Schaerli et al., 2000). This data laid the groundwork for 
recent studies in mice and humans that have expanded the knowledge of TFH, 
which are best defined on the basis of phenotypic marker expression such as a 
high surface expression of CXCR5, PD-1, and inducible T cell co-stimulator 
(ICOS) and a low expression of CCR7 (Bauquet et al., 2009; Chen et al., 2012; 
N. Chevalier et al., 2011; Choi et al., 2011; Crotty, 2011; Ma, Deenick, Batten, & 
Tangye, 2012; Schaerli et al., 2000; Yoo, Fish, & Braciale, 2012). CCR7 is 
expressed in various lymphoid tissues where it activates B and T lymphocytes 
and controls the migration of memory T cells to inflamed tissues and of non-TFH 
CD4 T cells to the T-zone of lymphoid tissues, due to presence of specific 
ligands CCL19 and CCL21. 
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 B cell lymphoma (Bcl-6) is a transcription factor that has been coined the 
“master regulator” of TFH differentiation (Crotty, 2011). Bcl-6 not only promotes 
TFH development, but it also prevents differentiation of naïve CD4 T cells into 
Th1, Th2, and Th17 cells by antagonizing blimp-1, a transcription factor that 
promotes the development of the remaining T helper subsets (Johnston et al., 
2009). However, some groups have questioned TFH as a terminally 
differentiated CD4 T cell lineage and suggest plasticity within these cells 
(Cannons, Lu, & Schwartzberg, 2013; Ma et al., 2012). Studies in mice have 
shown that antigen presentation by dendritic cells initiates differentiation of naïve 
CD4 T cells and early TFH differentiation is characterized by: 
• Increased PD-1, ICOS, and CXCR5 expression. These markers are 
progressively upregulated throughout differentiation (Crotty, 2011). 
• Decreased expression of CCR7, the receptor for chemokines CCL19 and 
CCL21, which localize cells within the T cell region of lymph nodes. CCR7 
expression is downregulated as TFH differentiation progresses (Kroenke 
et al., 2012). 
• Production of IL-6 and IL-21 cytokines, which act in an autocrine manner 
driving TFH differentiation (Nurieva et al., 2008). 
As differentiation progresses, the reciprocal expression of CXCR5 and CCR7 
permits the translocation of TFH from the T cell zone into the follicular region of 
lymph nodes. Here, ICOS ligand (ICOSL) expressing B cells maintain 
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differentiation of TFH (Choi et al., 2011). The fully polarized state of TFH is 
reached shortly after entering the follicular region of the lymph node.  
 The distribution of TFH throughout various lymphoid compartments has 
been shown to be proportional to the amount of follicular regions within each 
respective compartment, as well as the frequency of antigen exposure. Tonsils, 
which are continually exposed to various antigens, have been shown to display 
the highest overall frequency of TFH, followed by the spleen and lymph nodes 
(Crotty, 2011; Kim et al., 2001). Despite the identification of CXCR5+CD4 T cells 
within peripheral blood, the presence of true TFH cells in circulation has been a 
source of intense debate (Streeck, D'Souza, Littman, & Crotty, 2013).  This has 
brought about the need for proper phenotypic definitions and functional assays to 
define peripheral CXCR5+ CD4 T cells in the circulation. Coupled with this debate 
is the question of the existence of memory TFH cells, an area that requires more 
research before a definite answer can be reached.  
 Once localized in the lymphoid follicle, dynamic interactions between TFH, 
follicular dendritic cells, and B cells permit the formation of GCs where B cell 
proliferation and maturation occur. Specifically, TFH contributes to this 
development through the induction of Bcl-6 in GC B cells through a series of cell 
surface receptor interactions (CD40 Ligand and B cell Activation Factor (BAFF)) 
as well as the production of IL-21 and IL-4 cytokines (Batten et al., 2010; Crotty, 
2011; Eto et al., 2011). Confirming the importance of TFH in the GC, IL-21 
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deficient mice have been observed to have a reduced GC activity when 
compared to wild type mice (Eto et al., 2011).  
 Within the GC, TFH continually provide pro-survival and proliferative 
signals directed toward B cells allowing for affinity maturation and class switch 
recombination (CSR) to occur. There has yet to be a direct link between TFH and 
affinity maturation or CSR even though activation induced cytidine deaminase, a 
crucial factor in these processes, is expressed alongside Bcl-6 (Basso et al., 
2012). Nevertheless, it is believed that a thorough TFH response is associated 
with highly specific antibody responses, particularly IgG and IgA, suggesting 
effective B cell maturation (Streeck et al., 2013). 
 
TFH and HIV/SIV 
 Although TFH has been extensively studied in mice and tonsils from 
humans, little is known of TFH in the nonhuman primate model, particularly in the 
context of SIV.  Future work involving TFH in NHPs will provide insight to the 
pathogenicity of TFH dysregulation as well as a potential role for TFH in vaccine 
strategies.  
 The emergence of TFH coupled with the widely accepted HIV/SIV induced 
dysregulation of the GC and B cell functioning have sparked interest in the 
dynamics of TFH during HIV/SIV infection. It was originally hypothesized based 
on the behavior of other activated CD4 T cell subsets that TFH cells are 
susceptible to infection by HIV/SIV, thus making them prone to dysfunction and 
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depletion. This was partially verified in both humans and macaques by the 
presence of HIV/SIV RNA within TFH cells (Petrovas et al., 2012). Surprisingly, 
however, TFH populations displayed an increased frequency during chronic 
infection that has not been observed in other CD4 T cell lineages (Lindqvist et al., 
2012; Petrovas et al., 2012). Recently, it was found that TFH are functionally 
impaired during HIV infection suggesting an additional source of HIV-induced 
pathogenesis (Cubas et al., 2013). Despite this finding, additional work needs to 
be performed to provide a more detailed picture of these cells during HIV/SIV 
infection.  
 Measuring the functional characteristics of TFH during HIV/SIV infection 
has proven troublesome primarily due to their hypothetical absence from the 
blood in humans and the overall scarcity of these cells throughout lymphoid 
compartments in humans and macaques. Moreover, the lack of antibodies with a 
good reactivity to the CXCR5 of macaques have made difficult to isolate this 
subset to study its role in the HIV pathogenesis or in protection from SIV infection 
in macaques.  
 Three recent studies have shown that non-specifically stimulated TFH, as 
expected, produce high amounts of IL-21 and IL-4 in HIV-infected human and 
SIV-infected macaques, respectively (Hong, Amancha, Rogers, Ansari, & 
Villinger, 2012; Lindqvist et al., 2012; Petrovas et al., 2012). Quantification of IL-
21 mRNA transcripts has been used and has suggested increased expression of 
IL-21 in TFH populations versus non-TFH populations during SIV infection 
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(Petrovas et al., 2012). HIV-specific TFH have recently been identified and have 
been found to produce, in addition to IL-21, IFN-γ and TNF-α when stimulated 
with HIV-gag and HIV-gp120 peptides, respectively (Lindqvist et al., 2012). 
Nevertheless, there is a need for more effective mechanisms to measure the 
functionality of TFH, particularly in the ability to induce specific antibody 
responses, within humans and macaques infected with HIV/SIV. Not only will this 
provide insight to the behavior of TFH during infection, but it may also allude to 
the possibility of vaccine-induced TFH as a goal for future preventative HIV 
vaccine design strategies (Streeck et al., 2013). 
 
Objectives 
 T Follicular Helper cells play a critical role in B-cell maturation and 
antibody production and thus may play a role in HIV pathogenesis and in the 
induction of effective B cells upon vaccination. With the identification of a gp120-
specific antibody response in the RV144 vaccine trial as a correlate of protection, 
it is suggestive that TFH may contribute to this response through its intrinsic role 
in the GC. The present study utilizes the macaque model of HIV infection to:  
• Evaluate the frequency and function of T Follicular Helper cells within 
lymph nodes, spleen, tonsils, and blood of SIV negative macaques  
• Measure phenotypic and functional changes of TFH during chronic SIV 
infection  
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• Develop a series of novel assays to yield an enrichment of TFH from 
mononuclear cells from lymph nodes in macaques, which can then be 
used to measure the function of B-cells. 
• Evaluate the functional characteristics of migrated TFH populations versus 
those defined solely based on phenotypic markers 
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METHODS 
Animal Model and Study Design 
 The animals used in this study were colony bread rhesus macaques 
(Macaca mulatta) obtained from Covance Research Products (Alice, TX). The 
animals were housed and maintained in accordance with the standards of the 
Association for the Assessment and Accreditation of Laboratory Animal Care 
(AAALAC). This study was carried out in strict accordance with the 
recommendations in the Guide for the Care and Use of Laboratory Animals of the 
National Institutes of Health. The Advanced BioScience Laboratories, Inc., 
Institutional Animal Care and Use Committee approved the protocol. All surgery 
was performed under general anesthesia, and all efforts were made to minimize 
suffering. All macaques were negative for simian retrovirus, simian T-cell 
leukemia virus type 1, and herpes B. The major histo-compatibility status was 
determined as previously described (Knapp, Lehmann, Piekarczyk, Urvater, & 
Watkins, 1997). 
 
Cell Processing 
 Peripheral blood and lymph node samples were taken at designated time 
points throughout the study. Spleen and tonsils were collected at sacrifice. 
Briefly, peripheral blood mononuclear cells (PBMC) were isolated by using the 
Isopaque-Ficoll technique that utilizes differential density gradients to extract 
PBMCs from whole blood as previously described (Böyum, 1968). Lymphocytes 
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were extracted from lymph nodes, spleen and tonsils by removing excess tissue, 
physically dismantling lymphoid structures and filtering using a 100um cell 
strainer (Cat no. 352360, BD Falcon). All samples were processed fresh and 
were cryopreserved in liquid nitrogen until assays were performed.  
 
Flow Cytometry 
 Cells were washed with PBS, and stained with a yellow fluorescent 
reactive die (LIVE/DEAD, Invitrogen) to measure cell viability and also surface 
stained for 30 minutes at room temperature with the following antibodies: Alexa 
Fluor 488-CXCR5 (Clone RF8B2), Alexa Fluor 700-CD3 (clone SP34-2), 
PerCPCy5.5-CD4 (Clone L200), PECy7-CCR7 (Clone 3D12) (all from BD 
Biosciences); PE-SLAM (Clone A12C7D4), APC-PD-1 (Clone EH12.2H7), Pacific 
Blue-ICOS (Clone C398.4A), APCCy7-CD27 (Clone 0323), FITC-CD20, PECy5-
CD95(clone DX2) (all from Biolegend); and ECD-CD20 (Clone B9E9) (Beckman 
Coulter). Excess antibodies were then removed via washing with PBS. Prior to 
intracellular staining, cells were permeabilized using Fixation and 
Permeabilization Solution (BD Biosciences) for 20 minutes at  +4°C. Cells were 
then stained intracellularly with PE-Bcl6 (Clone K112-91, BD Biosciences) for 45 
minutes at room temperature and washed in Permealization Buffer 
(eBioscience). After staining, cells were acquired on LSR II Flow Cytometry (BD 
Biosciences) and analyzed using FlowJo (Treestar, CA). 
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Migration Assays 
 All migration assays were carried out in 6-well plates (Cat No. 3506, 
Corning) using 5µm cell culture inserts (Catalog no. PIMP30R48, Millipore).  
Cryopreserved cells were thawed and rested overnight in R10: RPMI 1640 
medium supplemented with 10% Fetal Bovine Serum and 1% Antibiotic-
Antimycotic (Catalog no. 15240, Gibco). 
 A series of two migrations were performed using chemokines CCL21 
(Catalog No, 336-3C-025/CF, R&D Systems) and CXCL13 (Cat No. 801-CX, 
R&D Systems) both at a concentration of 1µg/ml and CCL19 at 0.75µg/ml 
(Catalog No. PHC1244, Gibco). Additionally, 40ng/ml of IL-6 (Catalog no. 206-IL-
010/CF, R&D Systems) was used throughout the assay.   
 The migration assays were carried out using approximately 50 x 106 
unsorted lymphocytes. In the fist migration, lymphocytes were reconstituted in 
1.5 ml of R10 supplemented with IL-6 and added to the transwell insert. The 
lower chamber mixture consisted of 2.5 ml R10, IL-6, CCL21 and CCL19. 
Migration was allowed to proceed for 1 hour at 37°C. After the allotted time, cells 
that migrated to the lower chamber were washed with R10 and reserved for 
phenotypic analysis and/or functional assays.  
 Cells that remained in the upper chamber were washed using R10 and 
reconstituted in the upper chamber mixture for the second migration consisting of 
R10, IL-6, CCL19, and CCL21 at the same volume and concentrations above. 
The lower chamber mixture was prepared using 1.5ml R10 in combination with 
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IL-6 and CXCL13. Cells were incubated at 37°C for 1 hour. After incubation, cells 
in the lower chamber were washed and reserved. 
 
In vitro cell stimulations 
 Migrated cell populations from the first and second chemotaxis assays 
were divided to yield approximately 1x106 cells per stimulation condition. To 
measure SIV-specific responses, cells were stimulated with env peptides at a 
concentration of 2µg/ml. For a positive control, 0.1µl/ml PMA and 0.5µl/ml 
ionomycin were used. Negative control included untreated cells. All stimulations 
were carried out in 1ml R10 and incubated at 37°C for 6 hours. After 1 hour, BD 
GolgiStop (Cat No. 51-2092KZ, BD Bioscience Pharmigen) was added to block 
cytokine release.  
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RESULTS 
 
CCR7 and PD-1 markers characterize non-TFH, intermediate, and TFH cells 
in the lymphoid tissues of naïve rhesus macaques 
 Previous studies in mice and humans have defined TFH in lymph nodes 
and tonsils on the basis of the expression of high levels of CXCR5, Bcl-6 and 
PD-1 within the memory CD4 T cell population (Bauquet et al., 2009; N. 
Chevalier et al., 2011; Choi et al., 2011; Crotty, 2011; Ma et al., 2012; Schaerli et 
al., 2000). Groups using macaques have characterized TFH in the lymph nodes 
of SIV positive and negative macaques using CCR7, ICOS, and PD-1 markers. 
Collectively, these markers are expressed on a subset of CD4 T cells that is 
enriched in TFH and define a population of CD4 T cells that can localized in the 
GC (Petrovas et al., 2012). In fact, TFH are negative for CCR7, while expressing 
high levels of ICOS and PD-1. 
 Much of the work on TFH in macaques has been focused specifically on 
TFH within the lymph nodes, while less attention has been given to other 
lymphoid compartments. Nevertheless, it has been generally accepted that TFH 
can be found at greater frequencies in both the spleen and tonsils, as well as 
within the Peyer’s patches in the small intestine (Mihalj, Kellermayer, & Balogh, 
2013). The presence of TFH, or a form of memory TFH, in the blood is presently 
a topic of debate (Streeck et al., 2013).  
 In order to shed light on the distribution of TFH in macaques, we 
separated mononuclear cells from axillary and mesenteric lymph nodes, spleen, 
 34 
tonsils and rectal mucosa of naïve non-infected macaques. We stained the cells 
with CCR7, ICOS, and PD-1 markers to measure the frequency of TFH in each 
of these compartments (Figure 3). Figure 3A shows the gating strategy on 
monocuclear cells isolated from an axillary lymph node of a naive non-infected 
macaque. We defined 3 populations within the memory (CD28+) CD4 T cell 
population: non-TFH: CCR7+/PD-1-/+; intermediate: CCR7+/PD-1++; and TFH: 
CCR7-/PD-1++(Figure 3A). Bcl-6 is the canonical marker for TFH. As expected, 
the TFH CCR7- /PD-1++ population did express higher intensities of Bcl-6 and 
ICOS when compared to the non-TFH population. Intermediate cells had 
intermediate levels of ICOS and Bcl-6 that tended to vary among animals. 
Nevertheless, the differential expression of Bcl-6 and ICOS confirms that a 
population defined as CD3+CD4+CD28+CD95+ CCR7-PD-1++ includes the TFH 
population.  
 The frequency of these 3 populations varied among different tissues, 
which is shown by the raw data obtained from the axillary lymph node, the spleen 
and the blood from one animal depicted in Figure 3B. A higher frequency of 
CCR7- /PD-1++ TFH cells was found in the spleen and lamina propria of the rectal 
mucosa when compared to the lymph nodes. A reduced frequency of TFH was 
found in the blood, suggesting that these cells either simply do not migrate to the 
blood or cannot be characterized based on the expression of CCR7 and PD-1. 
We did not observe differences between the frequency of TFH detected in the 
mesenteric and the axillary lymph nodes sampled from the same animals (data  
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Figure 3: Tissue distribution of TFH in 
macaques. (A) Gating strategy to define TFH. 
Singlet and CD3/live cells are gated. 3 
definable populations with respect to CCR7 
and PD-1 expression are shown within the 
memory (CD28+/-/CD95+) CD4 T cells: non-
TFH (CCR7+PD-1-) in blue, intermediate cells 
(CCR7+PD-1++) in green, and TFH (CCR7-PD-
1++) in red. (B) Raw data obtained from lymph 
node, spleen and blood from 1 macaque. (C) 
Bars represent the frequency ± standard 
deviation of each respective population in 
lymph nodes from 4 animals, spleen from 3 
and blood from 5 animals. 
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not shown), so the data obtained from this samples were pooled together.  The 
spleen contained the majority of intermediate cells (CCR7+ PD-1++) while the 
lymph nodes had the higher frequency of non-TFH (Figure 3C).  
 
Changes of the frequency of TFH during chronic SIV infection 
 Previous studies have noted an increased frequency of TFH in the lymph 
nodes of chronically HIV/SIV infected humans and macaques (Liovat et al., 2009; 
Petrovas et al., 2012). To confirm this observation, and to study whether this was 
true for the other lymphoid compartments, we collected lymph nodes, spleen, 
tonsils and blood from chronically SIV infected macaques (>12 weeks after 
infection). Mononuclear cells were stained to assess the frequency of TFH by 
flow cytometry (Figure 4A). To assess SIV-driven changes in cell frequency, we 
compared percentages of TFH, non-TFH and intermediate-cells subsets between 
naïve and SIV infected macaques. Interestingly, we observed a significant 
increase in the frequency of TFH (T test: p=0.0032), as well as intermediate cells 
(p=0.0128) only in lymph nodes where a significant decrease of non-TFH was 
also observed (p=0.0024) (Figure 4B, left panel). Surprisingly, we did not observe 
significant changes in the percentage of these 3 populations in the spleen upon 
SIV infection (Figure 4B, right panel). Due to the low number of tonsils sampled 
from naïve non-infected animals we could not assess changes at this site. 
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Figure 4: Changes in the tissue distribution and frequency of TFH during chronic SIV 
infection. (A) Bars show the average frequency ± standard deviation of TFH (red), non- TFH 
(blue) and intermediate cells (green) in tonsils from 3, lymph nodes from 10, and spleen from 5 
chronically infected macaques. (B) Raw data showing TFH in the lymph node of an SIV negative 
and an SIV infected animal. Cells were gated on singlet/live+/CD3+/CD4+/CD95+ cells. (C) 
Frequency of TFH, Non-TFH and intermediate cells in the lymph nodes and spleen of SIV 
negative and positive animals. Each symbol represents one animal. P values calculated by t-test. 
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Changes in the ability of TFH to produce cytokines during chronic SIV  
infection 
TFH are considered as CD4 T cells that provide help to B cells. Therefore, 
it has been shown that in mice their ability to produce inflammatory cytokines 
such as IFN-γ and TNF-α is reduced compared to non-TFH (Crotty, 2011). In 
mice and humans, TFH is largely characterized by the ability to produce IL-21 
and IL-4 (Kroenke et al., 2012). Nevertheless, studies have shown that upon 
stimulation with PMA-ionomycin and during chronic HIV infection that TFH are 
also capable of producing IFN-γ and TNF-α (Lindqvist et al., 2012). 
A recent study in humans has suggested that TFH may be functionally 
impaired during HIV infection, thus offering inadequate help to the B cell 
immunity (Cubas et al., 2013). Here, we performed an intracellular staining on 
mononuclear cells obtained from naive and chronically infected macaques to 
compare the frequency of TFH and non-TFH to produce IL-21, IL-17, IFN-γ, and 
TNF-α upon in vitro stimulation with PMA-ionomycin and with peptide pools 
overlapping SIV-envelope and -gag proteins (Figure 5). Stimulation with PMA-
ionomycin in naïve non-infected macaques resulted in similar production of IL-21, 
IFN-γ and TNF-α cytokines within the TFH and non-TFH populations defined as 
CCR7-PD-1++ and CCR7+PD-1-/+, respectively (Figure 5A). Chronic SIV infection 
did not result in an impaired production of IL-21 after stimulation with PMA-
ionomycin, contrary to what others observed (Onabajo, George, Lewis, & 
Mattapallil, 2013). When cells from SIV infected animals were stimulated with 
SIV-env and gag peptides, we specifically observed the loss of IL-21 cytokines 
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produced by TFH only, while non-TFH retained their ability to produce this 
cytokine (Figure, 5B). Interestingly, SIV infection did not affect the ability of TFH 
to produce IFN-γ and TNF-α. As previously described, there was a great 
reduction of IL-17 produced by all memory CD4 T cells in the SIV infected 
animals when compared to the naïve macaques. Of note, after stimulation with 
the env peptide, non-TFH (CCR7+PD-1-/+) produced high levels of IL-17 cytokine 
(Appendix I). 
 
Separation of TFH by in vitro migration to the CXCL13 chemokine 
The phenotypic differentiation of macaque’s TFH has been based on the 
CCR7, PD-1 and ICOS markers, as there is not a cross-reactive CXCR5 
antibody for this species. Moreover, many studies on TFH have reported that the 
localization of TFH in the GC is important for its function on B cells. In order to 
functionally identify TFH, we set up a novel in vitro migrational assay to CXCL13, 
a chemokine that is produced in the GC by follicular dendritic cells and human 
Th17 cells, but not Th1 or Th2 cells, and promotes the migration of B cells and 
TFH. First, we exposed mononuclear cells obtained from a lymph node of a 
naïve, non-infected macaque to CXCL13 to induce migration. The frequency of 
TFH, non-TFH and intermediate CD4 T cells was assessed before and after the 
migration by FACS analysis. This assay failed to significantly enrich the TFH 
population, possibly due to the greater frequency of non-TFH at this lymphoid  
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Figure 5: Cytokine production by CD4 T cells during in vitro stimulation. (A) Lymph node 
cells were stimulated with PMA from SIV negative (left) and SIV positive (right) macaques. Bars 
represent the frequency ± standard deviation of CCR7-PD-1-/+ and CCR7-PD-1++ CD4 T cells 
producing IL-21, IFN-γ, and TNF-α. (B) Cells from SIV positive were also stimulated with SIV-env 
(left) and SIV-gag (right) and analyzed for cytokine production.  
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site (data not shown). Thus, we ameliorated this assay by using a two-step 
migration protocol to yield a TFH enriched population. Initially, mononuclear cells 
were exposed to CCL19 and CCL21, two chemokines that promote the migration 
of cells within the T cell zone of lymph nodes, to attract CCR7 bearing cells (M1, 
Figure 6A). Cells not responsive to CCL19 and CCL21 were subsequently 
migrated to the CXCL13 chemokine (M2, Figure 6A). This two-step migration 
assay resulted in an enrichment of TFH versus non-TFH in axillary lymph nodes 
from a naïve macaque (Figure 6B, left panel). Furthermore, when defining TFH 
on the basis of high ICOS expression, the same enhancement of TFH was 
observed (Figure 6B, right panel) Importantly, the level of intensity of Bcl-6 was 
higher within the memory CD4 T cells that migrated to the CXCL13 respect to 
CD4 memory T cells that did not (Figure 6C). Of note, despite the higher 
frequency of TFH defined as CCR7-/PD-1++ in the lymph nodes of the infected 
animals, the same total number of cells were found to migrate to the CXCL13 
chemokine (M2- bottom). CD8 T cells and B cells also migrated to both 
CCL19/CCL21 and CXCL13. 
 
Functional characterization of CD4 T cell migrated to CCL19 /CCL21 and to 
CXCL13 from a lymph node of a naïve animal 
To validate our assay, we stimulated cells from a lymph node of a non-infected 
animal that migrated to CCL19/CCL21 and to CXCL13 with PMA ionomycin to 
measure their ability to produce IFN-γ, TNF-α, IL-21 and IL-17.  Interestingly,  
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Figure 6: Two-step migration assay. (A) 
Schematic representation of the 2-steps 
migration assays. Mononuclear cells were 
first migrated to CCL19/CCL21 chemokines 
(M1). Cells that did not migrate (M1 Top) 
were collected, washed and migrated to 
CXCL13 (M2) chemokine. (B) Phenotypic 
characterization of memory (CD95+) CD4 T 
cells before the migration and in M1 and M2 
bottoms.  Cells were stained with CCR7, 
ICOS and PD-1 markers and were gated on 
singlets/ live (C) Histogram shows Bcl-6 
expression in M1 versus M2 populations. 
 
 
B 
C 
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memory CD4 T cell that migrated to the CXCL13 chemokine were able to 
produce twice the amount of IL-21 than memory CD4 T cells that migrated to the 
CCL19/CCL21 chemokines, while they also produced less IFN-γ cytokine (Figure 
7A). CD4 T cells from the second migration (M2) were also capable of producing 
IL-17 cytokine but to a lesser extent than memory CD4 T cells migrated to 
CCL19/CCL21. Few CCR7-/PD-1++ cells migrated to the T-zone chemokines. To 
assess weather these cells were functionally distinct from the CCR7-/PD-1++ that 
were collected after M2, we measured the cytokines produced within the TFH 
populations. Of note, we observed that CCR7-/PD-1++ CD4 T cells that migrated 
to the CXCL13 were capable of producing six folds higher levels of IL-21 when 
compared to CCR7-/PD-1++ CD4 T cells that migrated to CCL19/CCL21 
chemokines (Figure 7B). Interestingly, the IFN-γ produced was low and no IL-17 
was observed within this subset of cells in M2, while it was detected M2, while it 
was detected in CCR7-/PD-1++ CD4 T cells recovered after the first migration 
(M1). 
 
Functional impairment of CD4 T cell migrated to CCL19 /CCL21 and to 
CXCL13 from a lymph node of a chronically infected animal 
 Recent studies have shown that TFH defined as CXCR5 obtained from 
lymph nodes of HIV positive individuals are impaired in their ability to produce IL-
21 (Cubas et al., 2013). Similarly, in lymph nodes from SIV infected macaques,  
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Figure 7: Functional characteristics of migrated populations of a naïve macaque. (A) 
Depicts IL-17 and IL-21 production in activated CD4 T cells from M1 (left, blue) and M2 (right, 
red) populations when unstimulated and stimulated with PMA-ionomycin (B) Shows IFN-γ, IL-21 
and IL-17 production after PMA stimulation from TFH populations within M1 and M2 populations. 
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TFH define as PD-1++ lack the capacity to produce IL-21 following stimulation 
with PMA-ionomycin (Onabajo et al., 2013). Contrary to this study, we did not 
observe differences in the ability of CCR7+/PD-1-/+  (non-TFH) and CCR7-/PD-1++ 
(TFH) to produce IL-21 following stimulation with PMA-ionomycin in uninfected 
versus SIV-infected macaques. This is possibly due to the fact that some CCR7-
/PD-1++ may not express CXCR5. We took advantage of our two-step migration 
assay as a way to separate CXCR5 positive cells, and migrated cells from a 
lymph node of an infected animal. In this case, we also obtained an enrichment 
of CCR7-/PD-1++ CD4 T cells after the second migration to CXCL13 chemokine 
(Figure 8). We then measured IFN-γ, TNF-α, IL-21 and IL-17 cytokines within the 
memory CD4 T cells  (Figure 8B).  Interestingly, CD4 T cells that migrated to the 
T-zone chemokines were capable of producing IL-21, similarly to the naïve 
animals, while no IL-21 production was observed from CD4 T cells migrated to 
the CXCL13, suggesting a profound de-regulation of CD4 T cells in the B cell 
zone of lymph nodes during SIV infection. As expected, IL-17 production was 
also impaired. Similar results were also obtained when mononuclear cells from 
the spleen of chronically infected macaques were tested (Appendix II) 
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Figure 8: Functionality as by cytokine production in M1 versus M2 populations during SIV 
infection.  (A) Raw data from a chemotaxis assay on a chronically SIV infected animal are 
shown. Premigration, M1 (blue), and M2 (red) were gated on singlets/liveCD3+/CD4+/CD95+ cells. 
Frequency of non-TFH, intermediate, and TFH cells was defined by CCR7/PD-1 (left) and 
ICOS/PD-1 (right). Bcl-6 expression is also shown as a histogram. (B) Production of IL-17 and IL-
21 without stimulation and when stimulated with PMA in M1 versus M2 is shown. 
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DISCUSSION 
 
CD4 T helper (Th) cells play an instrumental role in orchestrating adaptive 
immune responses to invading pathogens. Recently, a novel CD4 T cell named T 
follicular helper cells, which provide help to B cells for the generation of long-term 
protective humoral responses, has been described (Crotty, 2011; Schaerli et al., 
2000). Long-term humoral responses are key to any effective vaccine, thus 
finding ways to induce TFH through vaccination may improve strategies that 
have resulted in significant but limited protection from HIV infection, such as the 
Thai trial (Rerks-Ngarm et al., 2009). The Rhesus macaque is the preferred 
animal model to study HIV pathogenesis and to assess the efficacy of candidate 
vaccines for HIV. Thus, it is important to characterize TFH in this model with the 
aim to find ways to induce this subset and consequently ameliorate vaccine 
efficacy.  
Here, we first wanted to expand the current knowledge on the tissue 
distribution of TFH. To this aim, we used the CCR7, ICOS, and PD-1 markers to 
define subsets of memory CD4 T cells in the lymph nodes, spleen, tonsils and 
rectal mucosa of naïve non-infected macaques. TFH defined as CCR7-PD-1++ 
were found in greater frequency in the spleen, tonsils and rectal mucosa when 
compared to the lymph nodes. Because CCR7 is a typical homing marker for the 
lymph node, we found a high frequency of non-TFH, defined as CCR7+PD-1-/+ 
within this respective compartment. A less frequent subset was also found that 
has a high expression of both CCR7 and PD-1 (intermediate cells: CCR7+PD-
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1++). This subset may be a differentiating population, as it showed intermediate 
levels of ICOS and variable levels of Bcl-6 markers.  
 Other studies have shown that during HIV/SIV infection, the frequency of 
TFH increase in lymph nodes (Lindqvist et al., 2012; Petrovas et al., 2012). We 
confirmed this finding and expanded on the current knowledge in two ways: first, 
we showed that the intermediated cells were also increased in frequency during 
SIV infection in the lymph nodes, and second, we showed that the deregulation 
was limited to TFH in the lymph nodes and did not occur in the spleen.  
 Studies in mice have shown that TFH aid in B cell maturation by producing 
IL-21 and IL-4 cytokines, while they are less capable than other Th subsets to 
induce inflammatory cytokines such as IFN-γ or TNF-α (Kroenke et al., 2012). 
Recently, however, other studies performed in HIV/SIV negative or positive 
humans and macaques have shown that TFH produce high levels of IFN-γ and 
TNF-α after stimulation with PMA-ionomycin or HIV/SIV-env and gag peptides 
(Onabajo et al., 2013). Here, we looked at the ability of the three subsets of 
memory CD4 T cells defined on the basis of CCR7, PD-1 and ICOS expression 
to produce IFN-γ, TNF-α, IL-21 and IL-17 in lymph nodes of non-infected and 
chronically infected macaques. Surprisingly, when stimulated with PMA-
ionomycin, no differences were found in the ability of TFH and non-TFH to 
produce any of the cytokines analyzed. This is in contrast with recent data 
published by Onabajo et al., showing that TFH in macaques could be delineated 
with the single use of high PD-1 expression within memory CD4 T cells. We also 
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found that IL-21 could be produced by non-TFH as well as intermediate cells, 
with the latter also displaying a high capacity to produce IL-17. Following SIV 
infection, there were no differences observed in the ability of TFH and non-TFH 
to produce IL-21 after PMA-ionomycin stimulation. Interestingly, TFH were 
instead deeply impaired in the capacity to produce IL-21 following stimulation 
with SIV-env and gag peptides. This same dynamic, however, was not observed 
in the CCR7+PD-1-/+ population. Persistent IL-21 production by CCR7+ cells 
during SIV infection may therefore serve a compensatory role for the 
deregulation of CCR7- cells. The lack of IL-21 production from TFH may impact 
the antibody production and maturation of B cells. Further studies are needed to 
clarify the role of this deregulation on HIV/SIV pathogenesis.  
 TFH is best characterized not only by its phenotypic markers, but also by 
its localization within the GC. Indeed, the ability of TFH to persist within the GC, 
due to CXCR5 expression, is critical for TFH to carry out its innate function in GC 
development and in providing B cell help (Crotty, 2011; Kim et al., 2001). Thus, 
cells defined as CCR7-PD-1++ residing outside the GC may be functionally 
impaired when compared to GC-residing TFH cells. Moreover, the lack of a 
cross-reactive CXCR5 antibody for macaques has hindered the isolation of 
CXCR5+ cells for analysis as groups using human samples have done (N. 
Chevalier et al., 2011; Schaerli et al., 2000). Thus, we optimized a two-step 
migration assay aimed at overcoming this issue while still taking advantage of the 
dynamic interplay between CXCR5 expressing cells (TFH) and the follicle 
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homing chemokine, CXCL13. The migration assay provides an additional 
advantage over sorting CXCR5+ cells, as the sheer presence of this marker does 
not indicate migratory capacity. Migration is largely dependent upon the 
cumulative expression of several other markers, such as CCR7. Thus, 
establishing a migration assay based on the ligands for CXCR5 and CCR7 yields 
a population of more accurately defined TFH based on both phenotype and 
location.  
 We show here that this novel assay produced two distinct populations at 
each step: the first enriched in non-TFH and the second enriched in TFH cells 
that are distinct from one another both on a phenotypic and a functional basis. 
The levels of Bcl-6 measured on the total memory CD4 T cells were higher in the 
cells migrated to CXCL13 than those migrated to CCL19/CCL21. We then 
wanted to compare the validity of TFH and non-TFH defined in a manner 
dependent upon phenotype versus differential migration. We performed an 
intracellular staining on memory CD4 cells from lymph nodes of uninfected 
macaques that migrated to CCL19/CCL20 and cells that migrated to CXCL13, 
after in vitro stimulation with PMA-ionomycin. Interestingly, cells that migrated to 
the CXCL13 chemokine produced higher levels of IL-21 and lower levels of IFN-γ 
when compared to CD4 T cells that migrated through their CCR7 expression. 
Notably, when we focused on the phenotype defined TFH within the two migrated 
CD4 T cell populations, we observed a six-fold increase in IL-21 production from 
CCR7-PD-1++ cells migrated to CXCL13 than the fewer CCR7-PD-1++ cells that 
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were found in the first step of the migration. Thus, using both phenotype and 
location identifies a group of highly functional TFH cells with regard to cytokine 
production. 
 Additionally, SIV chronic infection resulted in a decreased production of IL-
21 from only TFH migrated to the CXCL13 chemokine, but not to the 
CCL19/CCL21 chemokines. In conclusion, we believe we have optimized a novel 
tool to study TFH in macaques based on their ability to localize in the GC of 
lymphoid tissues, while at the same time bypassing the lack of available reagents 
for this subset in macaques.  
 
Future plans 
 
 In this study we have identified a new assay to study TFH in macaques. 
We are planning to use this assay to: 
1- Identify vaccine induced TFH. In specific, we will measure the frequency 
of TFH in lymph nodes collected from 6 macaques before and after 
vaccination with a Thai trail –like strategy (ALVAC-SIV/gp120 protein in 
Alum). Also, we will stimulate cells in vitro with a pool of envelope peptides 
identical to what was used in the vaccine to study envelope-specific TFH. 
2- Study the role of TFH induced by vaccination in protection. In this 
laboratory, we have successfully reproduced the results of the Thai Trial in 
the macaque model, using vaccines that were similar to the human trial 
(ALVAC-SIV/gp120 protein Alum) and challenging with SIVmac251 with 
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repeated low-dose challenges intrarectally (Pegu et al., 2013; Vaccari, 
Keele, et al., 2013).  Lymph nodes from 12 animals were collected 2 
weeks after the last immunization and 2 weeks before the first intrarectal 
exposure with SIVmac251. We are planning to use mononuclear cells 
from this study to assess the importance of TFH in protection from 
acquisition. Specifically, we will correlate the frequency of TFH and the 
presence cytokines produced by TFH with the time of acquisition of 
infection, with the frequency of gp120-specific plasmablasts measured in 
the blood, and with antibody titer, ADCC and neutralizing antibodies.   
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APPENDIX I 
 
      A              B 
 
 
 
Appendix I: IL-17 production by CD4 T cells during in vitro stimulation. (A) Lymph node 
cells were stimulated with PMA-ionomycin from SIV negative (left) and SIV positive (right) 
macaques. Bars represent the frequency ± standard deviation of CCR7-PD-1-/+ and CCR7-PD-1++ 
CD4 T cells producing IL-17. (B) Cells from SIV positive were also stimulated with SIV-env (left) 
and SIV-gag (right) and analyzed for IL-17 production.  
CCR7neg CCR7pos
0
5
10
15
20
%
 I
L
-1
7
 p
ro
d
u
c
in
g
 m
e
m
o
ry
C
D
4
 T
 c
e
ll
s
 t
o
 e
n
v
CCR7neg CCR7pos
0
2
4
6
8
%
 I
L
-1
7
 p
ro
d
u
c
in
g
 m
e
m
o
ry
C
D
4
 T
 c
e
ll
s
 t
o
 P
M
A
-i
o
n
o
Env
SIV positiveSIV negative 
PMA-iono
CCR7neg CCR7pos
0
2
4
6
8
10
%
 I
L
-1
7
 p
ro
d
u
c
in
g
 m
e
m
o
ry
C
D
4
 T
 c
e
ll
s
 t
o
 P
M
A
-i
o
n
o
SIV positive
Gag
SIV positive
CCR7neg CCR7pos
0.0
0.2
0.4
0.6
0.8
1.0
%
 I
L
-1
7
 p
ro
d
u
c
in
g
 m
e
m
o
ry
C
D
4
 T
 c
e
ll
s
 t
o
 g
a
g
 54 
APPENDIX II 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
Appendix I: Functional characterization 
of TFH within the spleen of a chronically 
SIV infected macaque. (A) Shows the 
yielded populations after the two-step 
populated shown previously (Figures 5 and 
8). (B) The production of IFN-γ, IL-21, and 
IL-17 is shown after PMA stimulation in TFH 
cells from M1 versus M2 populations.  
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